Published in Stat Med on May 31, 2013
Bayesian methods for the design and interpretation of clinical trials in very rare diseases. Stat Med (2014) 1.14
"Threshold-crossing": A Useful Way to Establish the Counterfactual in Clinical Trials? Clin Pharmacol Ther (2016) 0.79
Innovative approaches for designing and analyzing adaptive dose-ranging trials. J Biopharm Stat (2007) 4.78
AKT/FOXO signaling enforces reversible differentiation blockade in myeloid leukemias. Cell (2011) 2.77
Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim: general concepts. Biom J (2006) 2.61
Therapeutic drug monitoring for everolimus in heart transplant recipients based on exposure-effect modeling. Am J Transplant (2004) 2.09
Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study. Lancet Neurol (2013) 1.76
Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results. Liver Transpl (2006) 1.56
Robustness of methods for blinded sample size re-estimation with overdispersed count data. Stat Med (2013) 1.39
Pharmacokinetics and electrocardiographic pharmacodynamics of artemether-lumefantrine (Riamet) with concomitant administration of ketoconazole in healthy subjects. Br J Clin Pharmacol (2002) 1.33
Combining MCMC with 'sequential' PKPD modelling. J Pharmacokinet Pharmacodyn (2009) 1.32
The effects of a flexible visual acuity-driven ranibizumab treatment regimen in age-related macular degeneration: outcomes of a drug and disease model. Invest Ophthalmol Vis Sci (2009) 1.15
Interaction trial between artemether-lumefantrine (Riamet) and quinine in healthy subjects. J Clin Pharmacol (2002) 1.10
Bayesian models for subgroup analysis in clinical trials. Clin Trials (2011) 1.07
Rivastigmine exposure provided by a transdermal patch versus capsules. Curr Med Res Opin (2007) 1.06
Immunophenotypic patterns of CD8+ T cell subsets expressing CD8alphaalpha and IL-7Ralpha in viremic, aviremic and slow progressor HIV-1-infected subjects. Clin Immunol (2007) 0.99
Everolimus therapeutic concentration range defined from a prospective trial with reduced-exposure cyclosporine in de novo kidney transplantation. Ther Drug Monit (2004) 0.98
Use of historical control data for assessing treatment effects in clinical trials. Pharm Stat (2013) 0.95
A Bayesian case study in oncology Phase I combination dose-finding using logistic regression with covariates. J Biopharm Stat (2009) 0.93
Time-patterns of annualized relapse rates in randomized placebo-controlled clinical trials in relapsing multiple sclerosis: a systematic review and meta-analysis. Mult Scler (2012) 0.88
Trends in annualized relapse rates in relapsing-remitting multiple sclerosis and consequences for clinical trial design. Mult Scler (2011) 0.87
Low systemic absorption and good tolerability of pimecrolimus, administered as 1% cream (Elidel) in infants with atopic dermatitis--a multicenter, 3-week, open-label study. Pediatr Dermatol (2005) 0.84
Everolimus in pulmonary transplantation: pharmacokinetics and exposure-response relationships. J Heart Lung Transplant (2006) 0.83
A practical guide to Bayesian group sequential designs. Pharm Stat (2013) 0.83
Robust meta-analytic-predictive priors in clinical trials with historical control information. Biometrics (2014) 0.83
Blinded sample size reestimation with count data: methods and applications in multiple sclerosis. Stat Med (2010) 0.83
The network meta-analytic-predictive approach to non-inferiority trials. Stat Methods Med Res (2012) 0.79
Therapeutic drug monitoring for everolimus in kidney transplantation using 12-month exposure, efficacy, and safety data. Clin Transplant (2005) 0.78
Discussion of the article by Trippa, Rosner, and Müller on Bayesian enrichment strategies for randomized discontinuation trials. Biometrics (2011) 0.75
Estimating time to disease progression comparing transition models and survival methods--an analysis of multiple sclerosis data. Biometrics (2013) 0.75
Modeling and simulations relating overall survival to tumor growth inhibition in renal cell carcinoma patients. Cancer Chemother Pharmacol (2015) 0.75
Optimal design of clinical trials with biologics using dose-time-response models. Stat Med (2014) 0.75
The impact of period effects on dose level contrasts in alternating cross-over designs for first-time-in-human studies. Pharm Stat (2011) 0.75
The current state of Bayesian methods in medical product development: survey results and recommendations from the DIA Bayesian Scientific Working Group. Pharm Stat (2013) 0.75
Population pharmacokinetics of fingolimod phosphate in healthy participants. J Clin Pharmacol (2011) 0.75
Designing a non-inferiority study in kidney transplantation: a case study. Pharm Stat (2011) 0.75
Blinded and unblinded internal pilot study designs for clinical trials with count data. Biom J (2013) 0.75